Having heard about a one day symposium on immunotherapy organised by Charles River, I headed over to Munich and the EORTC-NCI-AACR conference a day early… Providentially it seems, as the Lufthansa strike will likely affect a few travellers en route to the Triple and ASH/WCLC/SABCS conferences.
The focus of this excellent one day event was on ‘Mapping the future of cancer drug discovery.’
So what stood out as interesting and intriguing?
Quite a few things, as it turned out, including a novel target in cancer research that I haven’t come across before.
To learn more insights, subscribers can log-in below or you can click the blue button to sign up…
It’s Day 4 of our Road to AACR 2016 mini-series
In the run up to the start of the annual meeting of the American Association for Cancer Research (AACR) that takes place in New Orleans from April 16 -20, we’re highlighting some of the hot topics and interesting targets with data to be presented at the meeting (Twitter #AACR16).
We’ll be providing conference coverage from AACR both during and after the meeting. The program this year offers a veritable smorgasbord of choices, particularly in cancer immunotherapy. It’s going to be hard to cover every session we want to attend!
AACR will be webcasting many presentations, however, much of the work presented and discussed at AACR is unpublished and/or still a work in progress, so do check if a talk you are interested in will be webcast or not. The online meeting calendar indicates whether permission has been given and if all the slides will be included. If you really want to hear something do get to meeting rooms early; we expect the cancer immunotherapy sessions will be especially popular!
In today’s post we’re looking at what’s new at AACR 2016 for cancer immunotherapies that target IDO1 and TDO and their downstream effectors.
Tumor cells and myeloid cells in the microenvironment express high levels of indoleamine-2,3-dioxygenase 1 (IDO1). IDO1 is a rate-limiting enzyme in the degradation of the amino acid tryptophan (TRP). Depletion of tryptophan inhibits T cell responses.
Another route by which the tryptophan metabolic pathway can lead to immunosuppression is via the enzyme TRP-2,3-dioxygenase 2 (TDO), which may be an additional target for cancer immunotherapy. Some IDO1 inhibitors also inhibit TDO, others don’t, which makes for an interesting question as to whether you need a dual-targeted approach or not?
In this post we’re looking at:
- Some of the companies who have IDO1/TDO inhibitors in development – there is a surprising amount of activity!
- What is the right combination partner?
- Who is most likely to benefit from IDO1/TDO cancer immunotherapy?
Data at AACR 2016 may help us answer some of the above questions, and we’ve showcased a few of the relevant sessions and presentations for your AACR “dance card” if this is an area of interest.
Subscribers can login to read more or you can purchase access below. This post is Day 4 of our Road to AACR 2016 mini-series.